Further, we found that MYDGF has a direct effect on KCs, as evidenced by the attenuation of PA-induced inflammation and promotion of macrophage M2 polarization, demonstrating that MYDGF derived from myeloid cells protects against NAFLD partly by decreasing inflammation levels in KCs. This evidence concerns the gene MYDGF and metabolic dysfunction-associated steatotic liver disease.